Impax Settles Opana ER Antitrust Direct Buyers’ Class Action For $145M
CHICAGO — Generic drugmaker Impax Laboratories LLC has agreed to pay $145 million to settle a multidistrict litigation antitrust class action by direct purchasers alleging that the company violated the Sherman...To view the full article, register now.
Already a subscriber? Click here to view full article